Novo Nordisk A/S Novo Nordisk A/S

Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Ludovic Helfgott

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Sale of shares

 

c)

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 295.00

28,710

 

 

 

 

 

 

 

 

 

d)

Aggregated information

28,710 shares
DKK 8,469,450.00

 

e)

Date of the transaction

2025-08-07

 

f)

Place of the transaction

Nasdaq Copenhagen

 

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Attachment